Authors:
Kodama, EI
Kohgo, S
Kitano, K
Machida, H
Gatanaga, H
Shigeta, S
Matsuoka, M
Ohrui, H
Mitsuya, H
Citation: Ei. Kodama et al., 4 '-ethynyl nucleoside analogs: Potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro, ANTIM AG CH, 45(5), 2001, pp. 1539-1546
Authors:
Hachiya, A
Aizawa-Matsuoka, S
Tanaka, M
Takahashi, Y
Ida, S
Gatanaga, H
Hirabayashi, Y
Kojima, A
Tatsumi, M
Oka, S
Citation: A. Hachiya et al., Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4(+) cell clone 1-10 (MAGIC-5), ANTIM AG CH, 45(2), 2001, pp. 495-501
Authors:
Yoshizawa, S
Yasuoka, A
Kikuchi, Y
Honda, M
Gatanaga, H
Tachikawa, N
Hirabayashi, Y
Oka, S
Citation: S. Yoshizawa et al., A 5-day course of oral desensitization to trimethoprim/sulfamethoxazole (T/S) in patients with human immunodeficiency virus type-1 infection who werepreviously intolerant to T/S, ANN ALLER A, 85(3), 2000, pp. 241-244
Authors:
Gatanaga, H
Yasuoka, A
Kikuchi, Y
Tachikawa, N
Oka, S
Citation: H. Gatanaga et al., Influence of prior HIV-1 infection on the development of chronic hepatitisB infection, EUR J CL M, 19(3), 2000, pp. 237-239
Authors:
Tachikawa, N
Goto, M
Hoshino, Y
Gatanaga, H
Yasuoka, A
Wakabayashi, T
Katano, H
Kimura, S
Oka, S
Iwamoto, A
Citation: N. Tachikawa et al., Detection of Toxoplasma gondii, Epstein-Barr virus, and JC virus DNAs in the cerebrospinal fluid in acquired immunodeficiency syndrome patients with focal central nervous system complications, INTERN MED, 38(7), 1999, pp. 556-562
Authors:
Gatanaga, H
Aizawa, S
Kikuchi, Y
Tachikawa, N
Genka, I
Yoshizawa, S
Yamamoto, Y
Yasuoka, A
Oka, S
Citation: H. Gatanaga et al., Anti-HIV effect of saquinavir combined with ritonavir is limited by previous long-term therapy with protease inhibitors, AIDS RES H, 15(17), 1999, pp. 1493-1498
Authors:
Tanaka, M
Hirabayashi, Y
Gatanaga, H
Aizawa, S
Hachiya, A
Takahashi, Y
Tashiro, E
Kohsaka, T
Oyamada, M
Ida, S
Oka, S
Citation: M. Tanaka et al., Reduction in interleukin-2-producing cells but not Th1 to Th2 shift in moderate and advanced stages of human immunodeficiency virus type-1-infection:Direct analysis of intracellular cytokine concentrations in CD4(+) CD8(-) T cells, SC J IMMUN, 50(5), 1999, pp. 550-554
Authors:
Aizawa, S
Gatanaga, H
Ida, S
Sakai, A
Tanaka, M
Takahashi, Y
Hirabayashi, Y
Oka, S
Citation: S. Aizawa et al., Clinical benefits of resistance assay for HIV-specific protease inhibitors: when to check and in whom?, AIDS, 13(10), 1999, pp. 1278-1279